Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.

Saranya Chumsri, Elizabeth Harlos,Heshan Liu, Emily R. Stark, Aixa Elena Soyano Muller,Morgan Weidner,Lauren Cornell, Beverly J. Roseberry,Pooja Prem Advani,Brenda Ernst, Rohit Rao,Kostandinos Sideras,Alvaro Moreno-Aspitia, Maria I. Vazquez-Roque

JOURNAL OF CLINICAL ONCOLOGY(2023)

引用 0|浏览14
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要